1. Home
  2. ELVN vs ADV Comparison

ELVN vs ADV Comparison

Compare ELVN & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • ADV
  • Stock Information
  • Founded
  • ELVN 2016
  • ADV 1987
  • Country
  • ELVN United States
  • ADV United States
  • Employees
  • ELVN N/A
  • ADV N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • ADV Business Services
  • Sector
  • ELVN Health Care
  • ADV Consumer Discretionary
  • Exchange
  • ELVN Nasdaq
  • ADV Nasdaq
  • Market Cap
  • ELVN 1.1B
  • ADV 1.3B
  • IPO Year
  • ELVN 2020
  • ADV N/A
  • Fundamental
  • Price
  • ELVN $27.53
  • ADV $3.06
  • Analyst Decision
  • ELVN Strong Buy
  • ADV Strong Buy
  • Analyst Count
  • ELVN 3
  • ADV 1
  • Target Price
  • ELVN $34.33
  • ADV N/A
  • AVG Volume (30 Days)
  • ELVN 309.7K
  • ADV 744.4K
  • Earning Date
  • ELVN 11-07-2024
  • ADV 11-05-2024
  • Dividend Yield
  • ELVN N/A
  • ADV N/A
  • EPS Growth
  • ELVN N/A
  • ADV N/A
  • EPS
  • ELVN N/A
  • ADV N/A
  • Revenue
  • ELVN N/A
  • ADV $4,071,144,000.00
  • Revenue This Year
  • ELVN N/A
  • ADV N/A
  • Revenue Next Year
  • ELVN N/A
  • ADV $2.28
  • P/E Ratio
  • ELVN N/A
  • ADV N/A
  • Revenue Growth
  • ELVN N/A
  • ADV 0.71
  • 52 Week Low
  • ELVN $9.80
  • ADV $1.85
  • 52 Week High
  • ELVN $27.67
  • ADV $4.95
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 73.14
  • ADV 29.91
  • Support Level
  • ELVN $24.60
  • ADV $2.99
  • Resistance Level
  • ELVN $27.55
  • ADV $4.10
  • Average True Range (ATR)
  • ELVN 1.41
  • ADV 0.19
  • MACD
  • ELVN 0.40
  • ADV -0.07
  • Stochastic Oscillator
  • ELVN 98.56
  • ADV 6.31

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About ADV Advantage Solutions Inc.

Advantage Solutions Inc is the provider of outsourced sales and marketing solutions to consumer goods companies and retailers. It has a technology-enabled platform of sales and marketing services like headquarter sales, retail merchandising, in-store sampling, digital commerce, and shopper marketing. For brands and retailers of all sizes, the firm helps to get the right products on the shelf and into the hands of consumers. The company helps its clients to sell more while spending less. Advantage has offices throughout North America and strategic investments in select markets throughout Africa, Asia, Australia, and Europe through which it services the global needs of multinational, regional, and local manufacturers. Its services are provided across two segments sales and marketing.

Share on Social Networks: